The Antiprotozoal Drug Nitazoxanide Improves Experimental Liver Fibrosis in Mice

Kai-Xin Liu,Zeng-Yang Wang,Ya-Ting Ying,Rui-Miao Wei,De-Li Dong,Zhi-Jie Sun
DOI: https://doi.org/10.1016/j.bcp.2024.116205
IF: 6.1
2024-01-01
Biochemical Pharmacology
Abstract:Nitazoxanide is an FDA-approved antiprotozoal drug. Our previous studies find that nitazoxanide and its metabolite tizoxanide affect AMPK, STAT3, and Smad2/3 signals which are involved in the pathogenesis of liver fibrosis, therefore, in the present study, we examined the effect of nitazoxanide on experimental liver fibrosis and elucidated the potential mechanisms. The in vivo experiment results showed that oral nitazoxanide (75, 100 mg.kg(-1)) significantly improved CCl 4 - and bile duct ligation-induced liver fibrosis in mice. Oral nitazoxanide activated the inhibited AMPK and inhibited the activated STAT3 in liver tissues from liver fibrosis mice. The in vitro experiment results showed that nitazoxanide and its metabolite tizoxanide activated AMPK and inhibited STAT3 signals in LX-2 cells (human hepatic stellate cells). Nitazoxanide and tizoxanide inhibited cell proliferation and collagen I expression and secretion of LX-2 cells. Nitazoxanide and tizoxanide inhibited transforming growth factor-beta 1 (TGF-beta 1)- and IL-6-induced increases of cell proliferation, collagen I expression and secretion, inhibited TGF-beta 1- and IL-6-induced STAT3 and Smad2/3 activation in LX-2 cells. In mouse primary hepatic stellate cells, nitazoxanide and tizoxanide also activated AMPK, inhibited STAT3 and Smad2/3 activation, inhibited cell proliferation, collagen I expression and secretion. In conclusion, nitazoxanide inhibits liver fibrosis and the underlying mechanisms involve AMPK activation, and STAT3 and Smad2/3 inhibition.
What problem does this paper attempt to address?